Amedeo Smart

Free Medical Literature Service

 

Amedeo

Ischemic Heart Disease
  Free Subscription

Articles published in
Am Heart J
    January 2026
  1. TSIGKAS G, Trigka-Vasilakopoulou A, Apostolos A, Papafaklis M, et al
    Distal versus conventional transradial artery access for coronary catheterization in patients with STEMI (DR-STEMI): Rationale and design of an international, multicenter, randomized trial.
    Am Heart J. 2026;291:73-80.
    >> Share

  2. GOLD M, Kulkarni S, Quyyumi A
    Response to letter by Hu regarding article, "Statistical Methodological Limitations and Improvement Suggestions in the Study of Vitamin D Deficiency and Cardiovascular Mortality After Heart Transplantation.".
    Am Heart J. 2026;291:218-219.
    >> Share

  3. HU H, Wang L
    Statistical methodological limitations and improvement suggestions in the study of vitamin D deficiency and cardiovascular mortality after heart transplantation.
    Am Heart J. 2026;291:216-217.
    >> Share

    December 2025
  4. MCCARTHY CP, Ballantyne CM, Blankstein R, Budoff MJ, et al
    Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics.
    Am Heart J. 2025;290:325-338.
    >> Share

  5. VAN DER LANDE ACMH, Diederiks NM, de Koning ER, Bosch J, et al
    Design and rationale of the HARTc 2.0 trial: A multicenter randomized controlled study on the impact of point-of-care high-sensitivity cardiac troponin-I testing in prehospital acute coronary syndrome triage on diagnosis and cost-effectiveness.
    Am Heart J. 2025;290:359-370.
    >> Share

    November 2025
  6. LINGAMSETTY SSP, Medarametla RVSK, Prajapati K, Jitta SR, et al
    Effects of Supersaturated Oxygen Therapy on Infarct Size and Microvascular Obstruction Following Myocardial Infarction: A Systematic Review and Meta-Analysis.
    Am Heart J. 2025 Nov 24:107311. doi: 10.1016/j.ahj.2025.107311.
    >> Share

  7. MONTALESCOT G, Bolognese L, Bartus S, Cequier-Fillat A, et al
    Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: Design of the AMUNDSEN Trial.
    Am Heart J. 2025 Nov 3:107295. doi: 10.1016/j.ahj.2025.107295.
    >> Share

  8. MAHMOUDI M, Nicholas Z, Jabbour RJ, Shambrook J, et al
    Anatomical, physiological and inflammatory characterization of non-culprit vessels in patients undergoing primary PCI for ST-elevation myocardial infarction in the presence of multivessel disease: Rationale and design of the PICNIC study.
    Am Heart J. 2025 Nov 3:107298. doi: 10.1016/j.ahj.2025.107298.
    >> Share

  9. SWOBODA PP, Berry C, McCann GP, Kelion A, et al
    Design and rationale of "a pragmatic approach to the investigation of stable chest pain: A UK, multicenter, randomized trial to assess patient outcomes, quality of life and cost effectiveness (CE-MARC 3)".
    Am Heart J. 2025;289:95-104.
    >> Share

    October 2025
  10. BOEDDINGHAUS J, Bima P, Crisanti L, Keller DI, et al
    PRospective Evaluation of the European Society of Cardiology 0/1h-algorithm;s Safety and Efficacy for Triage of Patients with Suspected Myocardial Infarction (PRESC1SE-MI): Rationale and design of a prospective international multicenter stepped-wedge
    Am Heart J. 2025 Oct 31:107299. doi: 10.1016/j.ahj.2025.107299.
    >> Share

  11. IGLESIAS JF, Leibundgut G, Heg D, Gasparini GL, et al
    Distal versus conventional radial large-bore access for percutaneous coronary intervention of complex coronary lesions: Rationale and design of the DISCO COMPLEX randomized superiority trial.
    Am Heart J. 2025 Oct 18:107291. doi: 10.1016/j.ahj.2025.107291.
    >> Share

  12. ABDELAZIZ A, Ramadan S, Hasan MT, Desouky M, et al
    Complete Revascularization in Patients with Acute Myocardial Infarction and Multivessel Disease: Pooled Analysis of Kaplan-Meier-Derived Individual-Patient-Data.
    Am Heart J. 2025 Oct 2:107284. doi: 10.1016/j.ahj.2025.107284.
    >> Share

  13. LEOSDOTTIR M, Dahlbom L, Back M, Wallentin L, et al
    Data quality assessment in the SWEDEHEART registry: Insights from serial audits on completeness and accuracy.
    Am Heart J. 2025;288:149-158.
    >> Share

    September 2025
  14. LERMAN JB, Koeberl DD, Epstein S, Roessig L, et al
    Developing Therapeutics for Rare Cardiovascular Diseases.
    Am Heart J. 2025 Sep 12:S0002-8703(25)00325-4. doi: 10.1016/j.ahj.2025.
    >> Share

  15. DE ROJAS JP, Toledo E, Estruch R, Guasch-Ferre M, et al
    Extra-Virgin Olive Oil and Additional Cardiovascular Outcomes in the PREDIMED Trial: An Outcome-Wide Perspective.
    Am Heart J. 2025 Sep 2:S0002-8703(25)00321-7. doi: 10.1016/j.ahj.2025.
    >> Share

  16. FEISTRITZER HJ, Jobs A, Zeymer U, Schneider S, et al
    Complete revascularization versus culprit-lesion only PCI in patients with NSTEMI and multivessel disease - Design and rationale of the randomized COMPLETE-NSTEMI trial.
    Am Heart J. 2025;287:94-106.
    >> Share

    August 2025
  17. DAGRES N, Gale CP, Nadarajah R, Boveda S, et al
    PRevention Of sudden cardiac death aFter myocardial Infarction by Defibrillator im-plantation: Design and Rationale of the PROFID EHRA randomised clinical trial.
    Am Heart J. 2025 Aug 5:S0002-8703(25)00289-3. doi: 10.1016/j.ahj.2025.
    >> Share

  18. REVAIAH PC, Serruys PW, Onuma Y, Andreini D, et al
    Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening - The VICTO
    Am Heart J. 2025 Aug 4:S0002-8703(25)00291-1. doi: 10.1016/j.ahj.2025.
    >> Share

  19. SARMA D, Smith R, Padkins M, Rali AS, et al
    Association between vasopressin administration and mortality in patients with cardiogenic shock.
    Am Heart J. 2025;286:88-96.
    >> Share

  20. DANDAMUDI K, Lawson BD, Barrett JC, Trankle CR, et al
    Trends of women in cardiovascular disease fellowships 2013-2022.
    Am Heart J. 2025;286:111-115.
    >> Share

    July 2025
  21. REINSTADLER SJ, Kronbichler A, Reindl M, Tiller C, et al
    Selective C-reactive protein apheresis in ST-elevation myocardial infarction: Design and rationale of the randomized CRP-STEMI trial.
    Am Heart J. 2025 Jul 28:S0002-8703(25)00283-2. doi: 10.1016/j.ahj.2025.
    >> Share

  22. HAN M, Kang J, Kim B, Hwang D, et al
    The impact of body mass index (BMI) on antiplatelet monotherapy strategy for secondary prevention after percutaneous coronary intervention: A sub-study of the HOST-EXAM trial.
    Am Heart J. 2025 Jul 5:S0002-8703(25)00214-5. doi: 10.1016/j.ahj.2025.
    >> Share

  23. ADAMS KN, Dickert NW, Stone GW, Facemire C, et al
    EARLY SUPPORT IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION COMPLICATED BY SHOCK. DESIGN OF EXCEPTION FROM INFORMED CONSENT PROCESSES IN RECOVER IV TRIAL.
    Am Heart J. 2025 Jul 2:S0002-8703(25)00204-2. doi: 10.1016/j.ahj.2025.
    >> Share

  24. MAKUVIRE TT, Latif Z, Atwater S, Shah MK, et al
    Health Care Access and Risk Factor Control in US adults with Cardiovascular Disease from 2015 to 2023.
    Am Heart J. 2025 Jul 2:S0002-8703(25)00208-X. doi: 10.1016/j.ahj.2025.
    >> Share

  25. KHAN E, Lambrakis K, Briffa T, Cullen LA, et al
    Re-engineering the clinical approach to suspected cardiac chest pain assessment in the emergency department by expediting research evidence to practice using artificial intelligence. (RAPIDx AI)-a cluster randomized study design.
    Am Heart J. 2025;285:106-118.
    >> Share

  26. DURAN AT, Barbecho JM, Shaw K, Ye S, et al
    Implementing depression treatment for cardiac populations in rapidly changing contexts: Design of the hybrid effectiveness-implementation IHEART DEPCARE trial.
    Am Heart J. 2025;285:52-65.
    >> Share

  27. PITARO N, Nicolas J, Sartori S, Shneyderman M, et al
    Impact of Left Ventricular Function on Outcomes in Patients with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention.
    Am Heart J. 2025 Jul 1:S0002-8703(25)00203-0. doi: 10.1016/j.ahj.2025.
    >> Share

    June 2025
  28. SHUKLA J, Schmidt C, Larson D, Murthy A, et al
    Clinical Outcomes and Discharge Disposition in Nonagenarians with ST-Elevation Myocardial Infarction.
    Am Heart J. 2025 Jun 27:S0002-8703(25)00202-9. doi: 10.1016/j.ahj.2025.
    >> Share

  29. HANIF M, Khan LA, Kulkarni A, Bhatia HS, et al
    Global lipoprotein (a) testing trends from 2015 to 2023.
    Am Heart J. 2025 Jun 21:S0002-8703(25)00199-1. doi: 10.1016/j.ahj.2025.
    >> Share

  30. BHATT AS, Go AS, Parikh RV, Ballance Z, et al
    Electronically Delivered, Cardiovascular-Focused Messaging to Improve Influenza Vaccination: Rationale, Design, and Baseline Characteristics of the KP-VACCINATE Megatrial.
    Am Heart J. 2025 Jun 18:S0002-8703(25)00196-6. doi: 10.1016/j.ahj.2025.
    >> Share

  31. HOPPER I, Marwick TH, Wolfe R, Amerena J, et al
    STAREE-HEART: a randomized placebo-controlled trial of atorvastatin effects on a marker of cardiac aging in older individuals without prior cardiovascular disease events: Protocol and baseline description of participants.
    Am Heart J. 2025 Jun 12:S0002-8703(25)00193-0. doi: 10.1016/j.ahj.2025.
    >> Share

  32. CUTLIP DE, Mehran R, Doros G, Kaplinskiy V, et al
    Prospective randomized single-blind multicenter study to assess the safety and effectiveness of the SELUTION SLR 014 drug eluting balloon in the treatment of subjects with in-stent restenosis: Rationale and design.
    Am Heart J. 2025;284:11-19.
    >> Share

    May 2025
  33. GENG Q, Ying Z, Zhenyan M, Renqiang Y, et al
    Long-term Prognostic Role of Persistent Microvascular Obstruction Determined by Cardiac Magnetic Resonance for ST-segment Elevation Myocardial Infarction.
    Am Heart J. 2025 May 29:S0002-8703(25)00187-5. doi: 10.1016/j.ahj.2025.
    >> Share

  34. MAINI AS, Abu-Much A, Redfors B, Wollmuth JR, et al
    Outcomes Among Patients with Coronary Bifurcation Lesions Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention.
    Am Heart J. 2025 May 22:S0002-8703(25)00176-0. doi: 10.1016/j.ahj.2025.
    >> Share

  35. WHITE HD, O'Brien SM, Boden WE, Fremes SE, et al
    Use of Coronary Artery Bypass Graft Surgery and Percutaneous Coronary Intervention and Associated Outcomes in the ISCHEMIA Trial.
    Am Heart J. 2025 May 20:S0002-8703(25)00165-6. doi: 10.1016/j.ahj.2025.
    >> Share

  36. GOLD ME, Kulkarni S, Yadalam A, Patel KJ, et al
    Cardiac Allograft Vasculopathy Mediates the Relationship Between Vitamin D Deficiency and Cardiovascular Mortality Following Heart Transplantation.
    Am Heart J. 2025 May 16:S0002-8703(25)00166-8. doi: 10.1016/j.ahj.2025.
    >> Share

  37. RAI B, Yildiz M, Bergstedt S, Bandari A, et al
    Diversity of Electrocardiographic Patterns in Left Main Culprit Acute ST-Elevation Myocardial Infarction.
    Am Heart J. 2025 May 14:S0002-8703(25)00164-4. doi: 10.1016/j.ahj.2025.
    >> Share

  38. MESSINGER MC, Ashburn NP, Chait JS, Snavely AC, et al
    Risk of delayed percutaneous coronary intervention for STEMI in the Southeast United States.
    Am Heart J. 2025 May 13:S0002-8703(25)00157-7. doi: 10.1016/j.ahj.2025.
    >> Share

  39. CARULLI E, McGarvey M, Chabok M, Panoulas V, et al
    Corrigendum to ;;Transcoronary cooling and dilution for cardioprotection during revascularisation for ST-segment elevation myocardial infarction: design and rationale of the STEMI-Cool study''. [Am Heart J. 2025:282:40-50].
    Am Heart J. 2025;288:89.
    >> Share

  40. JAMES S, Christoffersen AD, David JP, Hacker M, et al
    Effect of Once-Weekly Subcutaneous Semaglutide on Arterial Inflammation in People with Type 2 Diabetes and Cardiovascular Disease Using PET-MRI: Primary Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
    Am Heart J. 2025 May 7:S0002-8703(25)00156-5. doi: 10.1016/j.ahj.2025.
    >> Share

  41. KANDZARI DE, Latib A, Mylotte D, Ali ZA, et al
    Rationale and design of the prevail global trial program evaluating the prevail drug-coated balloon in patients with in-stent restenosis and de novo small vessel disease.
    Am Heart J. 2025;283:26-36.
    >> Share

    April 2025
  42. BERGER JS, Lyu C, Iturrate E, Westerhoff M, et al
    Opportunistic Assessment of Abdominal Aortic Calcification using Artificial Intelligence (AI) Predicts Coronary Artery Disease and Cardiovascular Events.
    Am Heart J. 2025 Apr 24:S0002-8703(25)00137-1. doi: 10.1016/j.ahj.2025.
    >> Share

  43. SOH CH, Chen J, Marwick TH
    Incidence Rate of Coronary Atherosclerosis among Cancer Types during Survivorship: A Systematic Review and Meta-Analysis.
    Am Heart J. 2025 Apr 23:S0002-8703(25)00142-5. doi: 10.1016/j.ahj.2025.
    >> Share

  44. CROOIJMANS C, Jansen T, van de Hoef TP, Paradies V, et al
    Design and rationale of the efficacy of endothelin receptor antagonism in treatment of coronary artery spasm: a randomized controlled trial (EDIT-CAS).
    Am Heart J. 2025 Apr 22:S0002-8703(25)00138-3. doi: 10.1016/j.ahj.2025.
    >> Share

  45. DILLINGER JG, Pezel T, Batias L, Angoulvant D, et al
    Twice-a-day administration of aspirin in patients with diabetes mellitus or aspirin resistance after acute coronary syndrome: Rationale and design of the randomized ANDAMAN trial.
    Am Heart J. 2025 Apr 21:S0002-8703(25)00132-2. doi: 10.1016/j.ahj.2025.
    >> Share

  46. LI L, Sun H, Jin Z, Li J, et al
    Positive outcome trials driven by reduction in nonfatal myocardial infarction: A systematic review and relevant guideline recommendations.
    Am Heart J. 2025 Apr 18:S0002-8703(25)00136-X. doi: 10.1016/j.ahj.2025.
    >> Share

  47. HAKEEM A, Ali Shah J, Kumar R, Khan K, et al
    Rationale and Design of the TADCLOT Trial: A Double Blind Randomized Controlled Trial Comparing Twice a Day Clopidogrel vs. Ticagrelor in Reducing Major Cardiac Events in Patients with Acute STEMI Undergoing Primary Percutaneous Coronary Intervention.
    Am Heart J. 2025 Apr 12:S0002-8703(25)00103-6. doi: 10.1016/j.ahj.2025.
    >> Share

  48. NATHAN A
    Response to letter by Ferguson regarding article, "Revenues, costs, and contribution margins of major inpatient cardiovascular procedures within the Medicare population.".
    Am Heart J. 2025 Apr 10:S0002-8703(25)00126-7. doi: 10.1016/j.ahj.2025.
    >> Share

  49. FERGUSON M
    Letter by Ferguson regarding article, "Revenues, costs, and contribution margins of major inpatient cardiovascular procedures within the Medicare population.".
    Am Heart J. 2025 Apr 9:S0002-8703(25)00125-5. doi: 10.1016/j.ahj.2025.
    >> Share

  50. SOMSEN YBO, de Winter RW, Wu J, Hoek R, et al
    Design and rationale of the drug-coated balloon coronary angioplasty versus stenting for treatment of disease adjacent to a chronic total occlusion (Co-CTO) trial.
    Am Heart J. 2025 Apr 7:S0002-8703(25)00105-X. doi: 10.1016/j.ahj.2025.
    >> Share

  51. KULASINGAM A, Laustsen S, Busk M, Sand NP, et al
    Rationale and Design of VICAD-RISK study: Visualization of Coronary Artery Disease for Modification of Risk Factors.
    Am Heart J. 2025 Apr 3:S0002-8703(25)00107-3. doi: 10.1016/j.ahj.2025.
    >> Share

  52. PINCOMBE A, Gray J, Hickling S, Sanfilippo F, et al
    Cost-effectiveness of the transition from Conventional to High-Sensitivity Troponin Assay for the Investigation and Management of Suspected Acute Coronary Syndrome in the Emergency Department.
    Am Heart J. 2025 Apr 2:S0002-8703(25)00104-8. doi: 10.1016/j.ahj.2025.
    >> Share

  53. CHO L, Nicholls SJ, Nordestgaard BG, Landmesser U, et al
    Design and rationale of Lp(a)HORIZON trial: Assessing the effect of Lipoprotein(a) lowering with Pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a).
    Am Heart J. 2025 Apr 2:S0002-8703(25)00101-2. doi: 10.1016/j.ahj.2025.
    >> Share

    March 2025
  54. HOFMANN R, James S, Sundqvist MO, Warme J, et al
    HELicobacter Pylori screening to prevent gastrointestinal bleeding in patients with acute Myocardial Infarction(HELP-MI SWEDEHEART)Design and rationale of a cluster randomized, crossover, registry-based clinical trial.
    Am Heart J. 2025 Mar 27:S0002-8703(25)00096-1. doi: 10.1016/j.ahj.2025.
    >> Share

  55. NOORY N, Westin O, Borgersen EH, Kragelund C, et al
    Absence of Coronary Artery Disease in Patients Undergoing Coronary Imaging and Association with Amyloidosis - A Danish Nationwide Study.
    Am Heart J. 2025 Mar 26:S0002-8703(25)00093-6. doi: 10.1016/j.ahj.2025.
    >> Share

  56. ZEYMER U, Hassinger F, Bramlage P, Schafer A, et al
    Hyperoxemic Oxygen Therapy in Patients with Acute Anterior Myocardial Infarction: HOT-AAMI - Design and Rationale of a Randomized Trial.
    Am Heart J. 2025 Mar 21:S0002-8703(25)00095-X. doi: 10.1016/j.ahj.2025.
    >> Share

  57. OSUDE N, Spall HV, Bosworth H, Krychtiuk K, et al
    Advancement of the Implementation of Evidence-based Therapies for Cardiovascular-Kidney-Metabolic Conditions: A Multi-Stakeholder Perspective.
    Am Heart J. 2025 Mar 17:S0002-8703(25)00084-5. doi: 10.1016/j.ahj.2025.
    >> Share

  58. ONUMA Y, Ninomiya K, Sjauw K, Damman P, et al
    Accuracy of Instantaneous Wave-free Ratio and Fractional Flow Reserve Derived From Single Coronary Angiographic Projections.
    Am Heart J. 2025 Mar 11:S0002-8703(25)00071-7. doi: 10.1016/j.ahj.2025.
    >> Share

  59. BERGMARK BA, Marston NA, Prohaska TA, Alexander VJ, et al
    Olezarsen in Patients with Hypertriglyceridemia at High Cardiovascular Risk: Rationale and Design of the Essence-TIMI 73b Trial.
    Am Heart J. 2025 Mar 11:S0002-8703(25)00072-9. doi: 10.1016/j.ahj.2025.
    >> Share

  60. YU J, Indraratna P, Briggs NE, Brown P, et al
    Rationale and design of the TeleClinical Care (TCC) -Cardiac trial: A pragmatic randomized trial of adjunctive virtual models of care in the secondary prevention of cardiovascular events.
    Am Heart J. 2025 Mar 11:S0002-8703(25)00091-2. doi: 10.1016/j.ahj.2025.
    >> Share

  61. SERPA F, Perera S, Cruz D, Figueroa JF, et al
    Cardiovascular Health, Lifestyle Factors, and Social Determinants Among Hispanic or Latino Adults in the United States.
    Am Heart J. 2025 Mar 9:S0002-8703(25)00070-5. doi: 10.1016/j.ahj.2025.
    >> Share

  62. LAI Y, Zhang S, Guo Y, Xu C, et al
    Apolipoprotein B modifies the association between lipoprotein(a) and ASCVD risk.
    Am Heart J. 2025;281:157-167.
    >> Share

  63. PATEL S, Fung M, Prasai S, Butalia S, et al
    Emergency department visits and hospitalizations after a diagnosis of angina with no obstructive coronary artery disease (ANOCA).
    Am Heart J. 2025 Mar 1:S0002-8703(25)00067-5. doi: 10.1016/j.ahj.2025.
    >> Share

    February 2025
  64. AUER J, Lamm G
    High-risk features and probability of ischemic and bleeding events after percutaneous coronary intervention.
    Am Heart J. 2025 Feb 26:S0002-8703(25)00058-4. doi: 10.1016/j.ahj.2025.
    >> Share

  65. JACOBSEN MR, Jabbari R, Grove EL, Maeng M, et al
    Genotype-guided de-escalation and abbreviation of dual antiplatelet therapy in patients with myocardial infarction and high bleeding risk: Design and rationale of the investigator-initiated, multicenter, randomized, controlled trial, DAN-DAPT.
    Am Heart J. 2025 Feb 25:S0002-8703(25)00059-6. doi: 10.1016/j.ahj.2025.
    >> Share

  66. TAKAHASHI T, Wei J, Iribarren AC, Gulati M, et al
    Rationale and design of the Women's Ischemia Syndrome Evaluation Mechanisms of Coronary Microvascular Dysfunction Leading to Pre-Heart Failure With Preserved Ejection Fraction (WISE Pre-HFpEF).
    Am Heart J. 2025 Feb 24:S0002-8703(25)00056-0. doi: 10.1016/j.ahj.2025.
    >> Share

  67. HAFF N, Horn DM, Bhatkhande G, Sung M, et al
    Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: rationale and design of a randomized controlled trial.
    Am Heart J. 2025 Feb 20:S0002-8703(25)00038-9. doi: 10.1016/j.ahj.2025.
    >> Share

  68. GIBSON CM, Bahit MC, Mehran R, Mehta SR, et al
    Oral Factor XIa Inhibitor Milvexian After a Recent Acute Coronary Syndrome: Rationale and Design of the Phase 3 (Librexia ACS).
    Am Heart J. 2025 Feb 20:S0002-8703(25)00044-4. doi: 10.1016/j.ahj.2025.
    >> Share

  69. ERRIQUEZ A, Colaiori I, Hakeem A, Guiducci V, et al
    Functional Coronary Angiography to Indicate and Guide Revascularization in STEMI Patients with Multivessel Disease: Rationale and Design of the AIR-STEMI trial: Functional coronary angiography in STEMI patients.
    Am Heart J. 2025 Feb 19:S0002-8703(25)00042-0. doi: 10.1016/j.ahj.2025.
    >> Share

  70. LEENING MJG, Khan CF, Zhu F, Singh SS, et al
    Lipoprotein(a) immunoassays and their associations with coronary artery calcification and aortic valve calcification.
    Am Heart J. 2025 Feb 18:S0002-8703(25)00040-7. doi: 10.1016/j.ahj.2025.
    >> Share

  71. TIAN Y, Wang X, Hu Z, Yu X, et al
    Design, rationale, and characterization of the Mobile health based OccuPational cardiovascular risk intErventioN study (mHealth-OPEN Study).
    Am Heart J. 2025 Feb 13:S0002-8703(25)00035-3. doi: 10.1016/j.ahj.2025.
    >> Share

  72. BAINEY KR, Welsh RC, Zheng Y, Arias-Mendoza A, et al
    Pharmaco-invasive Strategy and Dosing of Tenecteplase in STEMI Patients 60 to <75 Years: An Inter-trial Comparison of the STREAM-1 and STREAM-2 Trials: Comparison of Patients 60 to <75 Years in STREAM-1 and -2.
    Am Heart J. 2025 Feb 12:S0002-8703(25)00032-8. doi: 10.1016/j.ahj.2025.
    >> Share

  73. GAO XF, Kan J, Wu HY, Chen J, et al
    Intravascular Imaging-guided versus Angiography-guided Percutaneous Coronary Intervention in Patients with Diabetes Mellitus: Rationale and design of an International, Multicenter, Randomized IVI-DIABETES Trial.
    Am Heart J. 2025 Feb 4:S0002-8703(25)00017-1. doi: 10.1016/j.ahj.2025.
    >> Share

  74. WANG G, Zhang R, Chen SL, Wang J, et al
    Targeted Therapy with a Localized abluminal Groove Low-Dose Sirolimus-Eluting Bioabsorbable Polymer Coronary Stent in Chronic Total Occlusions: The TARGET CTO Non-Inferiority Randomized Trial.
    Am Heart J. 2025 Feb 3:S0002-8703(25)00018-3. doi: 10.1016/j.ahj.2025.
    >> Share

  75. MACHLINE-CARRION MJ, Girotto AN, Raupp P, Marton Pereira P, et al
    Rationale, design and pre-randomization data for a cluster randomized trial to assess the effect of a digitally enabled quality improvement intervention on LDL-C control in established atherosclerotic cardiovascular disease patients: The SAPPHIRE-LDL
    Am Heart J. 2025 Feb 3:S0002-8703(25)00020-1. doi: 10.1016/j.ahj.2025.
    >> Share

    January 2025
  76. STEG PG, Nicolas J, Baber U, Sartori S, et al
    Characterizing High-Risk Enrollment Criteria and Impact on Clinical Outcomes in a Large Randomized Clinical Trial: Insights From the TWILIGHT Trial.
    Am Heart J. 2025 Jan 29:S0002-8703(25)00016-X. doi: 10.1016/j.ahj.2025.
    >> Share

  77. EFTEKHARI A, Christiansen EH, Lassen JF, Raungaard B, et al
    Randomized comparison of the combined Sirolimus eluting and endothelial progenitor cell Combo(TM) stent vs. Biolimus eluting absorbable polymer coated BioMatrix Alpha(TM) stent in patients undergoing percutaneous coronary intervention. Rationale and s
    Am Heart J. 2025 Jan 25:S0002-8703(25)00013-4. doi: 10.1016/j.ahj.2025.
    >> Share

  78. EBRAHIMI M, Fonarow GC
    Higher Levels of Glucose within the Normal Range and Cardiovascular Risk: A Landscape Beyond Diabetes and Prediabetes.
    Am Heart J. 2025 Jan 23:S0002-8703(25)00008-0. doi: 10.1016/j.ahj.2025.
    >> Share

  79. PORTELA GT, Ducrocq G, Bertolet M, Alexander JH, et al
    Individualized transfusion decisions to minimize adverse cardiovascular outcomes in patients with acute myocardial infarction and anemia.
    Am Heart J. 2025 Jan 16:S0002-8703(25)00009-2. doi: 10.1016/j.ahj.2025.
    >> Share

  80. POLOMSKI EAS, Heemelaar JC, de Ronde MES, Al Jaff AAM, et al
    Increased Prevalence of Coronary Atherosclerosis in Cancer Survivors: A Retrospective Matched Cross-sectional Study with Coronary CT Angiography.
    Am Heart J. 2025 Jan 8:S0002-8703(25)00004-3. doi: 10.1016/j.ahj.2025.
    >> Share

  81. BRIX GS, Rasmussen LD, Rohde PD, Nissen L, et al
    Elevated lipoprotein(a) is independently associated with the presence of significant coronary stenosis in de-novo patients with stable chest pain.
    Am Heart J. 2025 Jan 7:S0002-8703(25)00001-8. doi: 10.1016/j.ahj.2025.
    >> Share

  82. VAN STEENWIJK MPJ, van Rosmalen J, Elzo Kraemer CV, Donker DW, et al
    A randomized embedded multifactorial adaptive platform for extra corporeal membrane oxygenation (REMAP ECMO) - design and rationale of the left ventricular unloading trial domain.
    Am Heart J. 2025;279:81-93.
    >> Share

    December 2024
  83. CARULLI E, McGarvey M, Chabok M, Panoulas V, et al
    Transcoronary cooling and dilution for cardioprotection during revascularisation for ST-segment elevation myocardial infarction: design and rationale of the STEMI-Cool study.
    Am Heart J. 2024 Dec 30:S0002-8703(24)00338-7. doi: 10.1016/j.ahj.2024.
    >> Share

  84. BURGESS S, Zaman S, Towns C, Coylewright M, et al
    The under-representation of women in cardiovascular clinical trials: State-of-the-art review and ethical considerations.
    Am Heart J. 2024 Dec 27:S0002-8703(24)00340-5. doi: 10.1016/j.ahj.2024.
    >> Share

  85. NELSON AJ, Kaltenbach LA, McGuire DK, Levya M, et al
    Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics.
    Am Heart J. 2024 Dec 21:S0002-8703(24)00336-3. doi: 10.1016/j.ahj.2024.
    >> Share

  86. XU L, Xu H, Wu S, Zhang H, et al
    Indobufen-based Dual Antiplatelet Therapy in Patients with Multivessel Coronary Disease Undergoing Drug-eluting Stent Implantation Insight From the OPTION Trial.
    Am Heart J. 2024 Dec 20:S0002-8703(24)00335-1. doi: 10.1016/j.ahj.2024.
    >> Share

  87. CASSESE S, Simonetti F, Covarrubias HAA, Janisch M, et al
    Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary Lithotripsy: Design and Rationale of ISAR-WAVE Trial.
    Am Heart J. 2024 Dec 20:S0002-8703(24)00337-5. doi: 10.1016/j.ahj.2024.
    >> Share

  88. POLLACK LM, Chang A, Thompson MP, Keteyian SJ, et al
    Hospital-level variation in cardiac rehabilitation metrics.
    Am Heart J. 2024 Dec 13:S0002-8703(24)00333-8. doi: 10.1016/j.ahj.2024.
    >> Share

  89. KAUL P, Barrett O, Savu A, Liyanage V, et al
    Association between adverse birth outcomes and long-term risk of premature cardiovascular disease and mortality in a contemporary population-based cohort of 502,383 pregnant women.
    Am Heart J. 2024 Dec 12:S0002-8703(24)00331-4. doi: 10.1016/j.ahj.2024.
    >> Share

  90. AARTS HM, Hemelrijk KI, Broeze GM, van Ginkel DJ, et al
    Deferral of routine percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation: rationale and design of the PRO-TAVI trial: the PRO-TAVI trial: rationale and design.
    Am Heart J. 2024 Dec 12:S0002-8703(24)00332-6. doi: 10.1016/j.ahj.2024.
    >> Share

  91. IKEMURA N, Chan PS, Gosch K, Nguyen DD, et al
    Health Status Outcomes after Acute Myocardial Infarction in Patients without Standard Modifiable Risk Factors.
    Am Heart J. 2024 Dec 3:S0002-8703(24)00317-X. doi: 10.1016/j.ahj.2024.
    >> Share

  92. REDDY KP, Shutlz K, Eberly LA, Khatana SAM, et al
    Revenues, costs, and contribution margins of major inpatient cardiovascular procedures within the Medicare population.
    Am Heart J. 2024 Dec 2:S0002-8703(24)00305-3. doi: 10.1016/j.ahj.2024.
    >> Share

  93. BUDGEON CA, Nidorf S, Mosterd A, Fiolet A, et al
    Exploration of the regional effects of colchicine in the LoDoCo2 trial.
    Am Heart J. 2024;278:186-194.
    >> Share

  94. KHAND A, Hatherley J, Dakshi A, Miller G, et al
    Safety and feasibility of triage and rapid discharge of patients with chest pain from emergency room: A pragmatic, randomized noninferiority control trial of the European Society of Cardiology (ESC) 0 to 1 hour pathway vs conventional 0 to 3 hour acce
    Am Heart J. 2024;278:235-247.
    >> Share

    November 2024
  95. ARAIZA-GARAYGORDOBIL D, Gopar-Nieto R, Sierra-Lara Martinez JD, S Ajit M, et al
    A randomized trial of antithrombotic therapy in patients with acute coronary syndrome and coronary ectasia.
    Am Heart J. 2024 Nov 28:S0002-8703(24)00304-1. doi: 10.1016/j.ahj.2024.
    >> Share

  96. FANAROFF AC, Vora AN, Wojdyla DM, Mehran R, et al
    Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS.
    Am Heart J. 2024 Nov 16:S0002-8703(24)00297-7. doi: 10.1016/j.ahj.2024.
    >> Share

  97. ENGEL-REBITZER E, Marinacci L, Zheng Z, Wadhera RK, et al
    Changes in coverage, access, and health status among adults with cardiovascular disease after medicaid work requirements.
    Am Heart J. 2024 Nov 14:S0002-8703(24)00276-X. doi: 10.1016/j.ahj.2024.
    >> Share

  98. NOORY N, Westin O, Maurer MS, Fosbol E, et al
    Chest pain and coronary artery disease in cardiac amyloidosis: Prevalence, mechanisms, and clinical implications.
    Am Heart J. 2024 Nov 14:S0002-8703(24)00296-5. doi: 10.1016/j.ahj.2024.
    >> Share

  99. ERLINGE D, Andersson J, Frobert O, Tornerud M, et al
    Rationale and design of INFINITY-SWEDEHEART: A registry-based randomized clinical trial comparing clinical outcomes of the sirolimus-eluting DynamX bioadaptor to the zotarolimus-eluting Resolute Onyx stent.
    Am Heart J. 2024;277:1-10.
    >> Share

  100. NAVAS-ACIEN A, Mark DB, Anstrom K, Lamas GA, et al
    Response to Tomoyuki Kawada: Blood and urine metal levels in patients with diabetes and cardiovascular disease.
    Am Heart J. 2024;277:143-144.
    >> Share

  101. KAWADA T
    Blood and urine metal levels in patients with diabetes and cardiovascular disease.
    Am Heart J. 2024;277:142.
    >> Share

    October 2024
  102. BARONE-ROCHETTE G, Vanzetto G, Danchin N, Steg PG, et al
    Rationale and design of the multicentric randomized EVAOLD trial: evaluation of a strategy guided by imaging versus routine invasive strategy in elderly patients with ischemia.
    Am Heart J. 2024 Oct 22:S0002-8703(24)00274-6. doi: 10.1016/j.ahj.2024.
    >> Share

  103. SHAH NP, Mulder H, Lydon B, Chiswell K, et al
    Real-World Exploration of LDL-Cholesterol Management in Patients with Atherosclerotic Cardiovascular Disease.
    Am Heart J. 2024 Oct 16:S0002-8703(24)00271-0. doi: 10.1016/j.ahj.2024.
    >> Share

  104. LUSK JB, Glover L, Soneji S, Granger CB, et al
    Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial.
    Am Heart J. 2024;276:110-114.
    >> Share

    September 2024
  105. VOLPP KG, Mahraj K, Norton LA, Asch DA, et al
    Design and Rationale of Penn Medicine Healthy Heart, a Randomized Trial of Effectiveness of a Centrally Organized Approach to Blood Pressure and Cholesterol Improvement Among Patients at Elevated Risk of Atherosclerotic Cardiovascular Disease.
    Am Heart J. 2024 Sep 26:S0002-8703(24)00262-X. doi: 10.1016/j.ahj.2024.
    >> Share

  106. KODAIRA M, Hasan MS, Grossman Y, Guerrero C, et al
    Risk of Cardiovascular Events after Influenza Infection-related Hospitalizations in Adults with Congenital Heart Disease -A Nationwide Population Based Study.
    Am Heart J. 2024 Sep 4:S0002-8703(24)00226-6. doi: 10.1016/j.ahj.2024.
    >> Share

  107. NELSON MD, Gomez-Arnold JM, Wei J, Lauzon M, et al
    Contributors to high left ventricular ejection fraction in women with ischemia and no obstructive coronary artery disease: Results from the Women's Ischemia Syndrome Evaluation - Coronary Vascular Dysfunction (WISE-CVD) Study.
    Am Heart J. 2024 Sep 2:S0002-8703(24)00224-2. doi: 10.1016/j.ahj.2024.
    >> Share

  108. DE COCK E, Kautbally S, Timmermans F, Bogaerts K, et al
    Low-dose colchicine for the prevention of cardiovascular events after percutaneous coronary intervention: rationale and design of the COL BE PCI trial: Short title: Rationale and design of the COL BE PCI trial.
    Am Heart J. 2024 Sep 2:S0002-8703(24)00225-4. doi: 10.1016/j.ahj.2024.
    >> Share

    August 2024
  109. HAMID H, Bagheri M, Benzing T, Krishnan S, et al
    Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the Tirzepatide treatment on coronary atherosclerosis progression: The (T-PLAQUE) randomized-controlled trial design: tirzepatide and plaque.
    Am Heart J. 2024 Aug 24:S0002-8703(24)00218-7. doi: 10.1016/j.ahj.2024.
    >> Share

  110. JIANG C, Wang Z, Du X, Wang Y, et al
    Protocol for a randomized controlled trial of intensive blood pressure control on cardiovascular risk reduction in patients with atrial fibrillation: rationale and design of the CRAFT trial.
    Am Heart J. 2024 Aug 23:S0002-8703(24)00203-5. doi: 10.1016/j.ahj.2024.
    >> Share

  111. BROWN TM
    Cholesterol Lowering Therapy is Highly Efficacious in Reducing Atherosclerotic Cardiovascular Disease Risk but Grossly Underutilized: How do we Move the Needle?
    Am Heart J. 2024 Aug 16:S0002-8703(24)00201-1. doi: 10.1016/j.ahj.2024.
    >> Share

  112. DISMORR M, Granbom-Koski M, Ellfors E, Ruck A, et al
    Sex differences and long-term clinical outcomes after transcatheter aortic valve replacement: a SWEDEHEART study.
    Am Heart J. 2024 Aug 9:S0002-8703(24)00185-6. doi: 10.1016/j.ahj.2024.
    >> Share

  113. AIHARA K, Torii S, Nakamura N, Hozumi H, et al
    Pathological Evaluation of Predictors for Delayed Endothelial Coverage After Currently Available Drug-eluting Stent Implantation in Coronary Arteries: Impact of Lesions With Acute and Chronic Coronary Syndromes.
    Am Heart J. 2024 Aug 7:S0002-8703(24)00197-2. doi: 10.1016/j.ahj.2024.
    >> Share

  114. STAHLI BE, Linke A, Westermann D, Van Mieghem NM, et al
    A Randomized Comparison of the Treatment Sequence of Percutaneous Coronary Intervention and Transcatheter Aortic Valve Implantation: Rationale and Design of the TAVI PCI Trial.
    Am Heart J. 2024 Aug 7:S0002-8703(24)00184-4. doi: 10.1016/j.ahj.2024.
    >> Share

  115. VOGEL B, Jou S, Sartori S, Farhan S, et al
    Impact of sex on outcomes associated with polyvascular disease in patients after PCI.
    Am Heart J. 2024 Aug 7:S0002-8703(24)00196-0. doi: 10.1016/j.ahj.2024.
    >> Share

    July 2024
  116. ERBAY A, Penzel L, Abdelwahed YS, Heuberger A, et al
    Prognostic impact of quantitative flow ratio (QFR)-consistent complete revascularization in patients with myocardial infarction and multivessel coronary artery disease.
    Am Heart J. 2024 Jul 19:S0002-8703(24)00177-7. doi: 10.1016/j.ahj.2024.
    >> Share

  117. SINGH K, Nikhare K, Gandral M, Aithal K, et al
    Rationale, Design and Baseline Characteristics of a Randomized Controlled Trial of a Cardiovascular Quality Improvement Strategy in India: The C-QIP Trial.
    Am Heart J. 2024 Jul 19:S0002-8703(24)00174-1. doi: 10.1016/j.ahj.2024.
    >> Share

  118. VERGHESE D, Hamal S, Ghanem A, Kinninger A, et al
    Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients with STable CoROnary Artery Disease CoMpared to Placebo (EKSTROM) Trial - Rationale and Design.
    Am Heart J. 2024 Jul 17:S0002-8703(24)00171-6. doi: 10.1016/j.ahj.2024.
    >> Share

    June 2024
  119. JEYAPRAKASH P, Pathan F, Ozawa K, Robledo KP, et al
    Restoring microvascular circulation with diagnostic ultrasound and contrast agent: Rationale and Design of the REDUCE trial.
    Am Heart J. 2024 Jun 27:S0002-8703(24)00162-5. doi: 10.1016/j.ahj.2024.
    >> Share

  120. WU ZM, Kan J, Ye F, You W, et al
    PCSK9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Randomized, Double- Blind, Placebo-Controlled, Multicenter SHAWN Study.
    Am Heart J. 2024 Jun 26:S0002-8703(24)00157-1. doi: 10.1016/j.ahj.2024.
    >> Share

  121. D'ENTREMONT MA, Lee SF, Mian R, Kedev S, et al
    Design and Rationale of the CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine versus placebo and Spironolactone versus placebo in Patients with Myocardial Infarction.
    Am Heart J. 2024 Jun 25:S0002-8703(24)00161-3. doi: 10.1016/j.ahj.2024.
    >> Share

  122. RAMASESHAN R, Perera D, Reid A, Andiapen M, et al
    REGENERATE-COBRA: A Phase II randomized sham-controlled trial assessing the safety and efficacy of intracoronary administration of autologous bone marrow-derived cells in patients with refractory angina.
    Am Heart J. 2024 Jun 9:S0002-8703(24)00146-7. doi: 10.1016/j.ahj.2024.
    >> Share

  123. SONG L, Guan C, Yu M, Sun Z, et al
    Sirolimus-eluting iron bioresorbable scaffold versus cobalt-chromium everolimus-eluting stents in patients with coronary artery disease: rationale and design of the IRONMAN-II trial.
    Am Heart J. 2024 Jun 3:S0002-8703(24)00140-6. doi: 10.1016/j.ahj.2024.
    >> Share

    May 2024
  124. MOK Y, Lu Y, Ballew SH, Sang Y, et al
    Premorbid physical activity and prognosis after incident myocardial infarction: the Atherosclerosis Risk in Communities Study.
    Am Heart J. 2024 May 7:S0002-8703(24)00120-0. doi: 10.1016/j.ahj.2024.
    >> Share

  125. KIM Y, Park H, Yoon HJ, Suh J, et al
    Fully Automated Quantitative Coronary Angiography Versus Optical Coherence Tomography Guidance for Coronary Stent Implantation (FLASH): Study Protocol for a Randomized Controlled Non-Inferiority Trial.
    Am Heart J. 2024 May 7:S0002-8703(24)00119-4. doi: 10.1016/j.ahj.2024.
    >> Share

  126. ZHANG F, Tian M, Wang X, Zhang H, et al
    Rationale and design of a Single-center Randomized Trial to Compare the Graft Patency between the Radial Artery and the No-touch Saphenous Vein in Coronary Artery Bypass Grafting Surgery (GRAFT-CAB Study).
    Am Heart J. 2024 May 4:S0002-8703(24)00117-0. doi: 10.1016/j.ahj.2024.
    >> Share

  127. NICHOLLS SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, et al
    Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in Participants With or at High Risk for Atherosclerotic Cardiovascular Disease: Rationale and Designs of BROADWAY and BROOKLYN.
    Am Heart J. 2024 May 3:S0002-8703(24)00116-9. doi: 10.1016/j.ahj.2024.
    >> Share

  128. COOPER JG, Ferguson J, Donaldson LA, Black KMM, et al
    Could paramedics use the HEART Pathway to identify patients at low-risk of myocardial infarction in the prehospital setting?
    Am Heart J. 2024;271:182-187.
    >> Share

    April 2024
  129. SAPP JL, Tang ASL, Parkash R, Stevenson WG, et al
    A Randomized Clinical Trial of Catheter Ablation and Antiarrhythmic Drug Therapy for Suppression of Ventricular Tachycardia in Ischemic Cardiomyopathy: The VANISH2 Trial.
    Am Heart J. 2024 Apr 20:S0002-8703(24)00096-6. doi: 10.1016/j.ahj.2024.
    >> Share

  130. KIM MC, Ahn JH, Hyun DY, Lim Y, et al
    Timing of fractional flow reserve-guided complete revascularization in patients with ST-segment elevation myocardial infarction with multivessel disease: Rationale and design of the OPTION-STEMI trial.
    Am Heart J. 2024 Apr 17:S0002-8703(24)00078-4. doi: 10.1016/j.ahj.2024.
    >> Share

  131. DAUBERT MA, Stebbins A, Peragallo-Urrutia R, Chiswell K, et al
    Early Postpartum Blood Pressure Screening is Associated with Increased Detection of Cardiovascular Risk Factors in Women with Hypertensive Disorders of Pregnancy.
    Am Heart J. 2024 Apr 4:S0002-8703(24)00076-0. doi: 10.1016/j.ahj.2024.
    >> Share

  132. PARK DY, Jamil Y, Babapour G, Kim J, et al
    Association of Cardiovascular Diseases with Cognitive Performance in Older Adults.
    Am Heart J. 2024 Apr 2:S0002-8703(24)00077-2. doi: 10.1016/j.ahj.2024.
    >> Share

    March 2024
  133. THOMAS A, Banna S, Shahu A, Ali T, et al
    Propofol vs etomidate for induction prior to invasive mechanical ventilation in patients with acute myocardial infarction.
    Am Heart J. 2024 Mar 28:S0002-8703(24)00074-7. doi: 10.1016/j.ahj.2024.
    >> Share

  134. WU Y, Hu L, Xie X, Li W, et al
    Different Dose Aspirin Plus Immunoglobulin (DAPI) for Prevention of Coronary Artery Abnormalities in Kawasaki Disease: Study Protocol for a Multi-centre, Prospective, Randomized, Open-label, Blinded End-point, Non-inferiority Trial.
    Am Heart J. 2024 Mar 18:S0002-8703(24)00071-1. doi: 10.1016/j.ahj.2024.
    >> Share

  135. KRUCOFF M, Spirito A, Baber U, Sartori S, et al
    Ticagrelor With or Without Aspirin Following Percutaneous Coronary Intervention in High-Risk Patients With Concomitant Peripheral Artery Disease: a subgroup analysis of the TWILIGHT randomized clinical trial.
    Am Heart J. 2024 Mar 6:S0002-8703(24)00053-X. doi: 10.1016/j.ahj.2024.
    >> Share

    February 2024
  136. MEHDIPOOR G, Redfors B, Chen S, Gkargkoulas F, et al
    Hypertension, Microvascular Obstruction and Infarct Size in Patients with STEMI Undergoing PCI: Pooled Analysis from 7 Cardiac Magnetic Resonance Imaging Studies.
    Am Heart J. 2024 Feb 29:S0002-8703(24)00050-4. doi: 10.1016/j.ahj.2024.
    >> Share

  137. ZIEGELSTEIN RC, Kronish IM, Thombs BD
    Depression Screening to Improve Clinical Outcomes in Coronary Heart Disease Patients.
    Am Heart J. 2024 Feb 22:S0002-8703(24)00044-9. doi: 10.1016/j.ahj.2024.
    >> Share

  138. LEE SH, Lee SJ, Heo JH, Ahn SG, et al
    Optimal antithrombotic strategy in patients with atrial fibrillation beyond 1 year after drug-eluting stent implantation: Design and rationale of the randomized ADAPT AF-DES trial.
    Am Heart J. 2024 Feb 22:S0002-8703(24)00041-3. doi: 10.1016/j.ahj.2024.
    >> Share

  139. DEHGHANI P, Singh J, Mancini GBJ, Stanberry L, et al
    Angiographic characteristics of Patients with STEMI and COVID-19 - Insights from NACMI Registry.
    Am Heart J. 2024 Feb 21:S0002-8703(24)00039-5. doi: 10.1016/j.ahj.2024.
    >> Share

    January 2024
  140. ALVIAR CL, Li BK, Keller NM, Bohula-May E, et al
    Prognostic Performance of the IABP-SHOCK II Risk Score Among Cardiogenic Shock Subtypes in the Critical Care Cardiology Trials Network Registry.
    Am Heart J. 2024 Jan 6:S0002-8703(23)00361-7. doi: 10.1016/j.ahj.2023.
    >> Share

    November 2023
  141. MUNHOZ D, Collet C, Mizukami T, Yong A, et al
    Rationale and design of the pullback pressure gradient (PPG) global registry.
    Am Heart J. 2023;265:170-179.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016